ENTRY       D12633                      Drug
NAME        Delandistrogene moxeparvovec (USAN/INN);
            Delandistrogene moxeparvovec-rokl;
            Elevidys (TN)
PRODUCT     ELEVIDYS (Sarepta Therapeutics)
REMARK      Product: D12633<US>
EFFICACY    Nervous system disease agent
  DISEASE   Duchenne muscular dystrophy [DS:H01963]
  TYPE      Gene therapy product
COMMENT     Recombinant adeno-associated virus AAVrh74 vector SRP-9001 MHCK7 promoter plus micro-dystrophin-specifyingTreatment of Duchenne muscular dystrophy
TARGET      DMD* [HSA_VAR:1756v1] [HSA:1756] [KO:K10366]
BRITE       Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Cellular process
               Cytoskeleton
                DMD* [HSA_VAR:1756v1]
                 D12633  Delandistrogene moxeparvovec (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             Cellular and gene therapy products
              D12633
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12633
DBLINKS     CAS: 2305040-16-6
///
